Adherence to NICE Technology Appraisal Guidance No 33: the use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer

Author： Mort D.   Jordan C.  

Publisher： Radcliffe Press

ISSN： 1475-9896

Source： Journal of Clinical Excellence, Vol.4, Iss.3, 2002-07, pp. : 310-311

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 58-63

Karger

Access to resources Recommend Favorite

Second-Line Treatment of Advanced Gastric Cancer with Oxaliplatin plus Raltitrexed

By  

Oncology Research and Treatment, Vol. 26, Iss. 3, 2003-07 ,pp. : 255-258

Karger

Access to resources Recommend Favorite

Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03)

By  

Oncology Research and Treatment, Vol. 33, Iss. 6, 2010-05 ,pp. : 295-299

Karger

Access to resources Recommend Favorite

Second-Line Treatment of Advanced Colorectal Cancer with a Biweekly Oxaliplatin plus Irinotecan Combination Regimen

By  

Oncology Research and Treatment, Vol. 25, Iss. 4, 2002-09 ,pp. : 358-362

Karger

Access to resources Recommend Favorite

Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 63, Iss. 3, 2002-10 ,pp. : 254-265

Karger

Access to resources Recommend Favorite